Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 20/20 | 0.72 |
| ▸ | MMP2 | P08253 | 18/20 | 0.72 |
| ▸ | MMP1 | P03956 | 8/20 | 0.72 |
| ▸ | MMP3 | P08254 | 1/20 | 0.72 |
| ▸ | MMP7 | P09237 | 1/20 | 0.72 |
| ▸ | MMP8 | P22894 | 1/20 | 0.72 |
| ▸ | MMP13 | P45452 | 1/20 | 0.72 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599348 | 1.00 | MMP9 (0.72) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7595722 | 1.00 | MMP9 (0.72) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7599560 | 1.00 | MMP9 (0.72) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7595612 | 1.00 | MMP9 (0.72) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7599342 | 0.89 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7599558 | 0.89 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7595608 | 0.89 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7595716 | 0.89 | MMP9 (0.70) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7599805 | 0.88 | MMP9 (0.73) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7600748 | 0.88 | MMP9 (0.73) | MMP9MMP2MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128496-A1 | Process for the preparation of matrix metalloproteinase inhibitors | ABBOTT LABORATORIES | 2002-09-12 | — | — | US | disclosed |
| US-6350902-B2 | REACTING HYDROXYAMINE WITH A TRIFLUOROFORMATE ESTER | ABBOTT LABORATORIES | 2002-02-26 | — | — | US | disclosed |
| US-20020002307-A1 | Process for the selective N-formylation of N-hydroxylamines | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| US-20010031896-A1 | Process for the selective N-formylation of N-hydroxylamines | ABBOTT LABORATORIES | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031896-A1 | Process for the selective N-formylation of N-hydroxylamines | HNMT, INMT, PNMT | MMP9 2786/4885MMP2 3410/4885MMP1 3507/4885 |
| US-20020002307-A1 | Process for the selective N-formylation of N-hydroxylamines | HNMT, INMT, PNMT | MMP9 2786/4885MMP2 3410/4885MMP1 3507/4885 |
| US-20020128496-A1 | Process for the preparation of matrix metalloproteinase inhibitors | MMP9, MMP2, MMP14 | MMP9 1/4885MMP2 2/4885MMP1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.